Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2-Reference-Cited by-同舟云学术

Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2

Published:2021-12 Issue:12 Volume:24 Page:103379
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Ohtsuka Junpei,Imai Masaki,Fukumura Masayuki,Maeda Mitsuyo,Eguchi Asami,Ono Ryoichi,Maemura Tadashi,Ito Mutsumi,Yamayoshi Seiya,Kataoka Yosky,Kawaoka Yoshihiro,Nosaka Tetsuya

Funder

Ministry of Education, Culture, Sports, Science and Technology

Japan Agency for Medical Research and Development

Mie University

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference48 articles.

1. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine;An;Sci. Adv.,2021

2. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N. Engl. J. Med.,2021

3. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge;Bolles;J. Virol.,2011

4. Outbreak of SARS-CoV-2 Infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings - Barnstable County, Massachusetts, July 2021;Brown;Morb. Mortal. Wkly. Rep.,2021

5. Rational vaccine design in the time of COVID-19;Burton;Cell Host Microbe,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control;Signal Transduction and Targeted Therapy;2024-09-11

2. Computational screening combined with well-tempered metadynamics simulations identifies potential TMPRSS2 inhibitors;Scientific Reports;2024-07-13

3. Mucosal adjuvanticity and mucosal booster effect of colibactin-depleted probiotic Escherichia coli membrane vesicles;Human Vaccines & Immunotherapeutics;2024-04-24

4. Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens;Vaccines;2023-10-12

5. Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein;2023-04-11